TN
Tango Therapeutics, Inc.
TNGX · NASDAQ
$22.33 +1.36% (+$0.30)
1M -8.89%
Market Cap $3.82B
P/E Ratio -
Div. Yield -
ROE 25.74%
Piotroski F-Score Weak
2/9Valuation
27 /100
Expensive P/B 3.73x
P/S 71.07x
EV/EBITDA N/A
Growth
97 /100
Growing Book val. growth 11.54%
Rev. growth 35.89%
FCF growth N/A
Profitability
20 /100
Weak Net margin 229.92%
Op. margin 253.38%
FCF margin 268.10%
Quality
1 /100
Poor ROE 25.74%
ROA 11.52%
Asset turnover 0.05x
Debt
100 /100
Low Current ratio 50.82x
Debt/Equity 0.03x
Net debt/EBITDA N/A
Stability
64 /100
Moderate Rev. volatility 18.74%
EPS volatility 18.67%
Profitable years 0
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre TNGX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Malte Peters
Employees
137
Headquarters
Boston
Evenimente viitoare
03 NOV.
Earnings
Upcoming earnings report